Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B
Jang-June Park,David K Wong,Abdus S Wahed,William M Lee,Jordan J Feld,Norah Terrault,Mandana Khalili,Richard K Sterling,Kris V Kowdley,Natalie Bzowej,Daryl T Lau,W Ray Kim,Coleman Smith,Robert L Carithers,Keith W Torrey,James W Keith,Danielle L Levine,Daniel Traum,Suzanne Ho,Mary E Valiga,Geoffrey S Johnson,Edward Doo,Anna S F Lok,Kyong-Mi Chang,Hepatitis B Research Network,Raymond T Chung,Lewis R Roberts,Adrian M Di Bisceglie,Mauricio Lisker-Melman,Harry L A Janssen,Joshua Juan,Colina Yim,Jenny Heathcote,Robert Perrillo,Son Do,Steven-Huy B Han,Tram T Tran,Stewart L Cooper,Robert J Fontana,Naoky Tsai,Michael W Fried,Keyur Patel,Donna Evon,Margaret Shuhart,Chia C Wang,Marc G Ghany,T Jake Liang,Steven Belle,Yona Cloonan,David Kleiner
DOI: https://doi.org/10.1053/j.gastro.2015.11.050
IF: 29.4
Gastroenterology
Abstract:Background & aims: T cells play a critical role in viral infection. We examined whether T-cell effector and regulatory responses can define clinical stages of chronic hepatitis B (CHB). Methods: We enrolled 200 adults with CHB who participated in the National Institutes of Health-supported Hepatitis B Research Network from 2011 through 2013 and 20 uninfected individuals (controls). Peripheral blood lymphocytes from these subjects were analyzed for T-cell responses (proliferation and production of interferon gamma and interleukin 10) to overlapping hepatitis B virus (HBV) peptides (preS, S, preC, core, and reverse transcriptase), influenza matrix peptides, and lipopolysaccharide. T-cell expression of regulatory markers FOXP3, programmed death-1, and cytotoxic T lymphocyte-associated antigen-4 was examined by flow cytometry. Immune measures were compared with clinical parameters, including physician-defined immune-active, immune-tolerant, or inactive CHB phenotypes, in a blinded fashion. Results: Compared with controls, patients with CHB had weak T-cell proliferative, interferon gamma, and interleukin 10 responses to HBV, with increased frequency of circulating FOXP3(+)CD127(-) regulatory T cells and CD4(+) T-cell expression of programmed death-1 and cytotoxic T lymphocyte-associated antigen-4. T-cell measures did not clearly distinguish between clinical CHB phenotypes, although the HBV core-specific T-cell response was weaker in hepatitis B e antigen (HBeAg)(+) than HBeAg(-) patients (percent responders: 3% vs 23%; P = .00008). Although in vitro blockade of programmed death-1 or cytotoxic T lymphocyte-associated antigen-4 increased T-cell responses to HBV, the effect was weaker in HBeAg(+) than HBeAg(-) patients. Furthermore, T-cell responses to influenza and lipopolysaccharide were weaker in CHB patients than controls. Conclusions: HBV persists with virus-specific and global T-cell dysfunction mediated by multiple regulatory mechanisms, including circulating HBeAg, but without distinct T-cell-based immune signatures for clinical phenotypes. These findings suggest additional T-cell-independent or regulatory mechanisms of CHB pathogenesis that warrant further investigation.